Alto Neuroscience Report issue

For profit Phase 2 Phase 4
Founded: Los Altos CA United States (2019)
Status: No NME R&D (2019)

Organization Overview

First Clinical Trial
2020
NCT04388202
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Alto Neuroscience

Active Ingredients

Drugs in Phase 4 Trials (4)

bupropion (wellbutrin) (1 trial)

duloxetine (Cymbalta) (1 trial)

escitalopram (lexapro) (1 trial)

sertraline (zoloft) (1 trial)

Drugs in Phase 2 Trials (2)

aceclofenac (3 trials)

alto-300 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 6